{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:05Z","timestamp":1761897005672},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ribavirin (RBV) is an antiviral drug that is part of the current standard therapy for chronic hepatitis C (CHC). It is enzymatically converted to ribavirin triphosphate (RTP) that inhibits the activity of viral RNA polymerase, thereby preventing viral replication. However, one of its adverse effects includes hemolytic anemia that limits its application. The variant of <jats:italic toggle=\"yes\">ITPA<\/jats:italic> (inosine triphosphatase), which dephosphorylates inosine triphosphate to inosine monophosphate, is a protective factor for RBV-induced anemia. RTP is an important metabolite required for ribavirin action. This study evaluated the time-dependent association of RTP concentrations in erythrocytes, RBV-induced toxicity, and virological response to RBV treatment for hepatitis C.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 28 Japanese patients with CHC were treated with RBV\/peg-interferon\/simeprevir or RBV\/sofosbuvir and were genotyped for <jats:italic toggle=\"yes\">ITPA<\/jats:italic> variants (<jats:italic toggle=\"yes\">rs1127354<\/jats:italic> and <jats:italic toggle=\"yes\">rs7270101<\/jats:italic>). We measured RTP concentrations in erythrocytes in a total of 76 samples collected at 4, 8, and 12 weeks from the initiation of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The <jats:italic toggle=\"yes\">ITPA rs1127354<\/jats:italic> variant was found in 7 patients. This was associated with significantly higher RTP concentrations in erythrocytes than in the wild-type patients (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Moreover, a significant correlation was observed between RTP concentrations and decline in hemoglobin (Hb) levels from baseline values in <jats:italic toggle=\"yes\">ITPA<\/jats:italic> wild type and <jats:italic toggle=\"yes\">rs1127354<\/jats:italic> variant 12 weeks after treatment initiation (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01; <jats:italic toggle=\"yes\">r<\/jats:italic> = \u22120.618 and \u22120.967, respectively). Multiple regression analysis revealed that <jats:italic toggle=\"yes\">ITPA<\/jats:italic> genotype and erythrocyte RTP concentrations were major factors associated with reduced Hb levels in RBV therapy for CHC. However, we did not find any association between erythrocyte concentrations and virological response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The increased tolerability to RTP concentrations in erythrocytes in the <jats:italic toggle=\"yes\">ITPA<\/jats:italic> variant <jats:italic toggle=\"yes\">rs1127354<\/jats:italic> plays a role in preventing RBV-induced severe anemia in this <jats:italic toggle=\"yes\">ITPA<\/jats:italic> variant.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000626","type":"journal-article","created":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T05:43:55Z","timestamp":1551591835000},"page":"497-502","source":"Crossref","is-referenced-by-count":4,"title":["Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype"],"prefix":"10.1097","volume":"41","author":[{"given":"Yoichi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Mizunuma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yokomori","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Kitasato University Medical Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"e0158512","DOI":"10.1371\/journal.pone.0158512","article-title":"Influence of ribavirin serum levels on outcome of antiviral treatment and anemia in hepatitis C virus infection","volume":"11","author":"Kuntzen","year":"2016","journal-title":"PLoS One."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2014.01.013","article-title":"Risk factors predictive of anemia development during telaprevir plus peginterferon\/ribavirin therapy in treatment-experienced patients","volume":"60","author":"Zeuzem","year":"2014","journal-title":"J Hepatol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2013.06.030","article-title":"Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients","volume":"59","author":"Scherzer","year":"2013","journal-title":"J Hepatol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1478-3231.2006.01354.x","article-title":"Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response","volume":"26","author":"Hung","year":"2006","journal-title":"Liver Int."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","article-title":"Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency","volume":"111","author":"Sumi","year":"2002","journal-title":"Hum Genet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","article-title":"ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\u2014a genome-wide study of Japanese HCV virus patients","volume":"139","author":"Ochi","year":"2010","journal-title":"Gastroenterology."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hepres.2005.10.003","article-title":"Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy","volume":"34","author":"Inoue","year":"2006","journal-title":"Hepatol Res."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/tmi.13027","article-title":"Peg-interferon and ribavirin treatment in HIV\/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics","volume":"23","author":"Smolders","year":"2018","journal-title":"Trop Med Int Health."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"e0144004","DOI":"10.1371\/journal.pone.0144004","article-title":"ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection","volume":"10","author":"Asselah","year":"2015","journal-title":"PLoS One."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FTD.0b013e31824bf778","article-title":"Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment","volume":"34","author":"D'Avolio","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"e0133879","DOI":"10.1371\/journal.pone.0133879","article-title":"Ribavirin concentrations do not predict sustained virological response in HIV\/HCV-coinfected patients treated with ribavirin and pegylated interferon in the Swiss HIV cohort study","volume":"10","author":"Kovari","year":"2015","journal-title":"PLoS One."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/jac\/dkv122","article-title":"Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin","volume":"70","author":"Rower","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2893.2010.01303.x","article-title":"Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2\/3 infection","volume":"18","author":"Pedersen","year":"2011","journal-title":"J Viral Hepat."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jcph.783","article-title":"Variant inosine triphosphatase phenotypes are associated with increased ribavirin triphosphate levels","volume":"57","author":"Jimmerson","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3851\/IMP2251","article-title":"A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms","volume":"17","author":"Krishnan","year":"2012","journal-title":"Antivir Ther."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/liv.12900","article-title":"Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients","volume":"36","author":"Lupo","year":"2016","journal-title":"Liver Int."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.108.145854","article-title":"The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1\u2212\/\u2212 mouse erythrocytes","volume":"329","author":"Endres","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/dku519","article-title":"SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir","volume":"70","author":"Milazzo","year":"2015","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:20:50Z","timestamp":1692051650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000626","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}